S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Price, News & Analysis

$4.65
+0.06 (+1.31%)
(As of 03/28/2024 ET)
Today's Range
$4.50
$4.71
50-Day Range
$3.41
$6.80
52-Week Range
$2.12
$7.22
Volume
113,100 shs
Average Volume
289,702 shs
Market Capitalization
$140.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Relmada Therapeutics MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
437.6% Upside
$25.00 Price Target
Short Interest
Bearish
5.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
1.01mentions of Relmada Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$350,305 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.53) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.44 out of 5 stars

Medical Sector

349th out of 938 stocks

Pharmaceutical Preparations Industry

153rd out of 425 stocks

RLMD stock logo

About Relmada Therapeutics Stock (NASDAQ:RLMD)

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

RLMD Stock Price History

RLMD Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Q4 2023 Relmada Therapeutics Inc Earnings Call
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Recap: Relmada Therapeutics Q4 Earnings
RLMD Apr 2024 2.500 put
Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc.
Relmada Therapeutics Inc RLMD
See More Headlines
Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLMD
Fax
N/A
Employees
14
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+437.6%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-98,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.84 per share

Miscellaneous

Free Float
26,101,000
Market Cap
$140.29 million
Optionable
Optionable
Beta
0.23

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Sergio Traversa M.B.A. (Age 64)
    Pharm.D., CEO & Director
    Comp: $719.04k
  • Mr. Maged S. Shenouda M.B.A. (Age 60)
    R.Ph., Chief Financial Officer
    Comp: $450.35k
  • Mr. Charles S. Ence CPA (Age 59)
    M.B.A., Chief Accounting & Compliance Officer
    Comp: $568.68k
  • Dr. Paolo Manfredi M.D. (Age 62)
    Ph.D., Chief Scientific Officer
  • Ms. Gina DiGuglielmo
    VP & Head of Clinical Operations
  • Dr. Marco Pappagallo M.D. (Age 65)
    Chief Clinical Officer
  • Mr. John Hixon
    Head of Commercial
  • Dr. Richard M. Mangano (Age 74)
    Consultant

RLMD Stock Analysis - Frequently Asked Questions

What is Relmada Therapeutics' stock price target for 2024?

0 brokerages have issued 12-month price targets for Relmada Therapeutics' stock. Their RLMD share price targets range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 437.6% from the stock's current price.
View analysts price targets for RLMD
or view top-rated stocks among Wall Street analysts.

How have RLMD shares performed in 2024?

Relmada Therapeutics' stock was trading at $4.14 at the beginning of 2024. Since then, RLMD shares have increased by 12.3% and is now trading at $4.65.
View the best growth stocks for 2024 here
.

When is Relmada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RLMD earnings forecast
.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($2.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.62) by $0.82.

What ETF holds Relmada Therapeutics' stock?

AdvisorShares Psychedelics ETF holds 150,158 shares of RLMD stock, representing 5.18% of its portfolio.

Who are Relmada Therapeutics' major shareholders?

Relmada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Parsons Capital Management Inc. RI (3.16%), Opaleye Management Inc. (2.91%), Mirae Asset Global Investments Co. Ltd. (0.90%), Point72 Asset Management L.P. (0.83%), Guild Investment Management Inc. (0.70%) and GSA Capital Partners LLP (0.61%). Insiders that own company stock include Cedric O'gorman, Charles J Casamento, Chuck Ence, Maged Shenouda, Paul Edward Kelly and Sergio Traversa.
View institutional ownership trends
.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLMD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners